(RIGL) Rigel Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 537m USD | Total Return: 47% in 12m
Avg Turnover: 9.67M
Qual. Beats: 0
Rev. Trend: 94.6%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 1.5 → Forward 6.5
Beneish M-Score -0.90 > -1.5 - likely earnings manipulation
Altman Z'' -12.30 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Rigel Pharmaceuticals, Inc. (RIGL) is a commercial-stage biotechnology company focused on hematology and oncology. The company’s primary revenue drivers include TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for relapsed/refractory AML with IDH1 mutations, and GAVRETO for RET fusion-positive lung and thyroid cancers.
The company operates within the high-risk biotechnology sector, where business models typically rely on heavy R&D investment and strategic collaborations, such as Rigel’s partnerships with MD Anderson Cancer Center and the CONNECT network. Its pipeline includes R289, an IRAK1/4 inhibitor targeting myelodysplastic syndrome and inflammatory diseases.
Biotechnology firms often face significant regulatory hurdles and patent expiration risks that can impact long-term valuation. Reviewing the fundamental metrics on ValueRay can provide further clarity on the companys financial health.
Headquartered in South San Francisco, Rigel maintains a specialized focus on small-molecule kinase inhibitors. This targeted approach allows the company to address niche patient populations with high unmet medical needs in the United States market.
- TAVALISSE sales growth in chronic immune thrombocytopenia market drives core product revenue
- REZLIDHIA adoption in relapsed acute myeloid leukemia impacts oncology portfolio valuation
- GAVRETO commercial integration and market share expansion in RET fusion-positive cancers
- Clinical trial data for IRAK1/4 inhibitor R289 influences long term pipeline outlook
- Strategic collaborations for olutasidenib expansion determine future royalty and milestone potential
| Net Income: 364.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -4.37 > 1.0 |
| NWC/Revenue: 48.22% < 20% (prev 39.36%; Δ 8.85% < -1%) |
| CFO/TA 0.16 > 3% & CFO 79.3m > Net Income 364.2m |
| Net Debt (-100.1m) to EBITDA (131.3m): -0.76 < 3 |
| Current Ratio: 2.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.7m) vs 12m ago 8.35% < -2% |
| Gross Margin: 93.39% > 18% (prev 0.90%; Δ 9.25k% > 0.5%) |
| Asset Turnover: 88.09% > 50% (prev 115.4%; Δ -27.31% > 0%) |
| Interest Coverage Ratio: 18.68 > 6 (EBITDA TTM 131.3m / Interest Expense TTM 6.90m) |
| A: 0.29 (Total Current Assets 234.0m - Total Current Liabilities 89.5m) / Total Assets 504.6m |
| B: -2.01 (Retained Earnings -1.01b / Total Assets 504.6m) |
| C: 0.38 (EBIT TTM 128.9m / Avg Total Assets 340.3m) |
| D: -9.69 (Book Value of Equity -1.01b / Total Liabilities 104.7m) |
| Altman-Z'' = -12.30 = D |
| DSRI: 0.81 (Receivables 49.9m/41.5m, Revenue 299.8m/203.1m) |
| GMI: 0.96 (GM 93.39% / 89.64%) |
| AQI: 3.36 (AQ_t 0.53 / AQ_t-1 0.16) |
| SGI: 1.48 (Revenue 299.8m / 203.1m) |
| TATA: 0.56 (NI 364.2m - CFO 79.3m) / TA 504.6m) |
| Beneish M = -0.90 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 29.19 with a total of 214,864 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by -4.79%,
over three months by -15.32% and
over the past year by +47.03%.
Rigel Pharmaceuticals has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold RIGL.
- StrongBuy: 1
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.2 | 82.3% |
P/E Forward = 6.4558
P/S = 1.7659
P/B = 1.3443
P/EG = -0.1
Revenue TTM = 299.8m USD
EBIT TTM = 128.9m USD
EBITDA TTM = 131.3m USD
Long Term Debt = 15.0m USD (from longTermDebt, last quarter)
Short Term Debt = 30.5m USD (from shortTermDebt, last quarter)
Debt = 46.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 864k
Net Debt = -100.1m USD (calculated: Debt 46.6m - CCE 146.7m)
Enterprise Value = 436.6m USD (536.7m + Debt 46.6m - CCE 146.7m)
Interest Coverage Ratio = 18.68 (Ebit TTM 128.9m / Interest Expense TTM 6.90m)
EV/FCF = 5.51x (Enterprise Value 436.6m / FCF TTM 79.3m)
FCF Yield = 18.16% (FCF TTM 79.3m / Enterprise Value 436.6m)
FCF Margin = 26.44% (FCF TTM 79.3m / Revenue TTM 299.8m)
Net Margin = 121.5% (Net Income TTM 364.2m / Revenue TTM 299.8m)
Gross Margin = 93.39% ((Revenue TTM 299.8m - Cost of Revenue TTM 19.8m) / Revenue TTM)
Gross Margin QoQ = 92.17% (prev 91.47%)
Tobins Q-Ratio = 0.87 (Enterprise Value 436.6m / Total Assets 504.6m)
Interest Expense / Debt = 14.81% (Interest Expense 6.90m / Debt 46.6m)
Taxrate = 25.76% (3.00m / 11.7m)
NOPAT = 95.7m (EBIT 128.9m * (1 - 25.76%))
Current Ratio = 2.62 (Total Current Assets 234.0m / Total Current Liabilities 89.5m)
Debt / Equity = 0.12 (Debt 46.6m / totalStockholderEquity, last quarter 399.9m)
Debt / EBITDA = -0.76 (Net Debt -100.1m / EBITDA 131.3m)
Debt / FCF = -1.26 (Net Debt -100.1m / FCF TTM 79.3m)
Total Stockholder Equity = 247.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 107.0% (Net Income 364.2m / Total Assets 504.6m)
RoE = 28.86% (Net Income TTM 364.2m / Total Stockholder Equity 1.26b)
RoCE = 10.09% (EBIT 128.9m / Capital Employed (Equity 1.26b + L.T.Debt 15.0m))
RoIC = 32.01% (NOPAT 95.7m / Invested Capital 298.9m)
WACC = 10.53% (E(536.7m)/V(583.3m) * Re(10.49%) + D(46.6m)/V(583.3m) * Rd(14.81%) * (1-Tc(0.26)))
Discount Rate = 10.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.51%
[DCF] Terminal Value 71.25% ; FCFF base≈61.7m ; Y1≈70.7m ; Y5≈104.1m
[DCF] Fair Price = 66.50 (EV 1.13b - Net Debt -100.1m = Equity 1.23b / Shares 18.5m; r=10.53% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.38 | # QB: 0
Revenue Correlation: 94.57 | Revenue CAGR: 48.55% | SUE: -0.36 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.06 | Chg30d=-93.93% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.27 | Chg30d=+5.31% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=3.09 | Chg30d=-35.66% | Revisions=+0% | GrowthEPS=-52.0% | GrowthRev=-8.3%
EPS next Year (2027-12-31): EPS=4.58 | Chg30d=-4.46% | Revisions=+0% | GrowthEPS=+48.4% | GrowthRev=+22.2%
[Analyst] Revisions Ratio: +20%